Bayer, Merck Hit In Pa. Court Over Avelox Nerve Damage
Law360, New York (May 26, 2015, 4:16 PM EDT) -- Bayer Corp. and Merck & Co. Inc. downplayed the risk of permanent nerve damage posed by the antibiotic Avelox and have promoted the drug for minor conditions that can be treated with safer medications, according to a complaint filed in Pennsylvania court on Friday.
Plaintiff Jacqueline Whitters alleged that she developed irreversible peripheral neuropathy after taking Avelox between 2012 and 2013 and accused the defendants of responding to reports of nerve problems with an amended label that understated the drug’s risks.
“Rather than warning patients and physicians that the use of Avelox may result in permanent nerve damage, defendants instead adopted...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!